New concepts in assessing sickle cell disease severity

American Journal of Hematology

Volumn 58, Issue 1, 1998, Pages 61-66

  Schnog, John John B ^a,b   Lard, Leroy R ^a,b   Rojer, Robert A ^a   Van Der Dijs, Fey P L ^c   Muskiet, Frits A J ^d   Duits, Ashley J ^a,b,e  

^a St Elisabeth Hospital Willemstad   (Netherlands Antilles)

^b Red Cross Bloodbank Curacao   (Netherlands Antilles)

^c Public Health Laboratory   (Netherlands Antilles)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e NONE   (Netherlands Antilles)

Author keywords

Severity parameters; Sickle cell disease; Vasoocclusion

Indexed keywords

COUMARIN ANTICOAGULANT; FOLIC ACID;

ARTICLE; CHRONIC PAIN; CLINICAL FEATURE; DISEASE SEVERITY; HUMAN; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VEIN OCCLUSION;

ANEMIA, SICKLE CELL; HUMANS; MODELS, CARDIOVASCULAR; PAIN; SEVERITY OF ILLNESS INDEX; VASCULAR DISEASES;

EID: 0031900314     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199805)58:1<61::AID-AJH11>3.0.CO;2-8     Document Type: Article

References (60)

1. Serjeant GR: Sickle-cell disease. Lancet 350:725, 1997.
2. Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762, 1997.
3. Serjeant GR: "Sickle Cell Disease." New York: Oxford University Press, 1985.
4. Powars D, Chan LS, Schroeder WA: The variable expression of sickle cell disease is genetically determined. Semin Hematol 27:360, 1990.
5. Platt OS, Thorington BD, Donald MS, Brambilla DJ, Milner PF, Rosse WF, Vichinski E, Kinney TR: Pain in sickle cell disease: Rates and risk factors. N Engl J Med 325:11, 1991.
6. Westerman MP, Bailey K, Freels S, Schlegel R, Williamson P: Assessment of painful episode frequency in sickle-cell disease. Am J Hematol 54:183, 1997.
7. Baum KF, Dunn DT, Maude GH, Serjeant GR: The painful crisis of homozygous sickle cell disease. A study of risk factors. Arch Intern Med 147:1231, 1987.
8. Pearson HA, Wethers D, Johnson S: Pain in sickle cell disease. N Engl J Med 325:1748, 1991 (letter).
9. Platt OS, Milner PF, Thorington BD, Rosse WF, Vichinsky E: Pain in sickle cell disease. N Engl J Med 325:1748, 1991 (letter).
10. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease. N Engl J Med 330:1639, 1994.
11. Powars DR, Chan LS: Is sickle cell crisis a valid measure of clinical severity in sickle cell anemia? In Nagel R (ed): "Progress in Clinical and Biological Research," Vol 240, New York: Liss, 1987, p 393.
12. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317, 1995.
13. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, Fondu P, Toppet M, Sabiran E: Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 88:1960, 1996.
14. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ: Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 128:820, 1996.
15. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P: Clinical and hematologic effects of hydroxyurea in children with sickle cell disease. J Pediatr 129:559, 1996.
16. Vichinsky EP: Comprehensive care in sickle cell disease: Its impact on morbidity and mortality. Semin Hematol 28:220, 1991.
17. Bloom M: "Understanding Sickle Cell Disease." Jackson: University Press of Mississippi, 1995.
18. Serjeant GR, Serjeant BE: Management of sickle cell disease: Lessons from the Jamaican Cohort Study. Blood Rev 7:137, 1993.
19. Westall J: Sickle cell disease is poorly managed. BMJ 314:396, 1997 (News).
20. Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH: Erythrocyte adherence to endothelium in sickle cell anemia. A possible determinant of disease severity. N Engl J Med 302:992, 1980.
21. Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M: Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow. Blood 70:152, 1987.
22. Setty BNY, Stuart MJ: Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: Potential role in sickle cell disease. Blood 88:2311, 1996.
23. Gee BE, Platt OS: Sickle reticulocytes adhere to VCAM-1. Blood 85:268, 1995.
24. 1- Integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 82:1891, 1993.
25. 1 and Glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82:3548, 1993.
26. 1 integrin receptors on sickle reticulocytes and fibronectin. Blood 88:4348, 1996.
27. Kasschau MR, Barabino GA, Bridges KR, Golan DE: Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 87:771, 1996.
28. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD: Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood 87:4440, 1996.
29. Hebbel RP, Vercellotti GM: The endothelial biology of sickle cell disease. J Lab Clin Med 129:288, 1997.
30. Malavé I, Perdomo Y, Escalona E, Rodriguez E, Anchustegui M, Malavé H, Arends T: Levels of tumour necrosis factor α/cachectin (TNF-α) in sera from patients with sickle disease. Acta Haematol 90:172, 1993.
31. Francis RB, Haywood J: Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 84:611, 1992.
32. Vordemeier S, Singh S, Biggerstaff J, Harrison P, Grech H, Pearson TC, Dumonde DC, Brown KA: Red blood cells from patients with sickle cell disease exhibit increased adherence to cultured endothelium pretreated with tumour necrosis factor. Br J Haematol 81:591, 1992.
33. Peters M, Plaat BEC, ten Cate H, Wolters HJ, Weening RS, Brandjes DPM: Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 71:169, 1994.
34. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS: Plasma tissue factor VII and thrombin-antithrombin levels indicate increased tissue factor activity in sickle-cell patients. Br J Haematol 81:539, 1992.
35. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, McIntire LV: Unusually large von Willebrand Factor Multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 80:905, 1987.
36. Lowenthal EA, Cornwell PE, Mayo MS, Thornley Brown: Homocysteine elevation occurs in adults with sickle cell disease. Blood 88(Suppl 1):492a, 1996 (abstr).
37. Houston P, Rana S, Sekhasari, Perlin E, Castro O: Homocysteine in sickle cell anemia: Relationship to stroke and disease severity. Blood 88(Suppl 2):17b, 1996 (abst).
38. Gearing AJ, Newman W: Circulating adhesion molecules in disease. Immunol Today 14:506, 1994.
39. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ: Soluble forms of adhesion molecules, E-selectin, ICAM-1, and VCAM-1: Pathological significance. Ann NY Acad Sci 667:324, 1992.
40. Pigott R, Dillon LP, Hemingway IH, Gearing AJH: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584, 1992.
41. Duits AJ, Pieters RC, Saleh AW, van Rosmalen E, Katenberg H, Berend K, Rojer RA: Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 81:96, 1996.
42. Platt OS: Easing the suffering caused by sickle cell disease. N Engl J Med 330:783, 1994.
43. Moore CM, Ehlayel M, Leiva LE, Soreson RU: New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol 76:385, 1996.
44. Styles LA, Lubin B, Vichinsky E, Laurence S, Hua M, Test S, Kuypers F: Decrease of very late activating antigen-4 and CD36 on reticylocytes in sickle cell patients treated with hydroxyurea. Blood 89:2554, 1997.
45. Cid MC: New developments in the pathogenesis of systemic vasculitis. Curr Opin Rheumatol 8:1, 1996.
46. Francis RB, Johnson CS: Vascular occlusion in sickle cell disease: Current concepts and unanswered questions. Blood 77:1405, 1991.
47. Adams DH, Andrew RL: Chemokines: Leucocyte recruitment and activation cytokines. Lancet 349:490, 1997.
48. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP: Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. Medicine 75:300, 1996.
49. D'Angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 90:1, 1997.
50. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinski E: Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 86:776, 1995.
51. Barnes PJ, Karin M: Nuclear factor NF-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066, 1997.
52. Griffin TC, McIntire D, Buchanan GR: High dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 330:733, 1994.
53. Wolters HJ, ten Gate H, Thomas LLM, Brandjes DPM, van der Ende A, van der Heiden Y, Statius van Eps LW: Low-intensity oral anticoagulation in sickle cell disease reverses the prethrombotic state: Promises for treatment? Br J Haematol 90:715, 1999.
54. Chen CC, Rosenbloom CL, Anderson DC, Manning AM: Selective inhibition of E selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of iκB-α phosphorylation. J Immunol 155:3538, 1995.
55. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, Van der Meer J, Gallus AS, Simmonneau G, Chesterman CH, Prins MH, Bossuyt PMM, De Haes H, Van den Belt AGM, Sagnard L, D'Azemar P, Büller: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334:682, 1996.
56. Gray NT, Barlett JM, Kolasa KM, Marcuard SP, Holbrook CT, Horner RD: Nutritional status and dietary intake of children with sickle cell anemia. Am J Ped Hematol 14:57, 1992.
57. Rabb LM, Grandison Y, Mason K, Hayes RJ, Serjeant B, Serjeant GR: A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 54:589, 1983.
58. Van den Berg H, Heseker H, Lamand M, Sandström B, Thurnham D: Flair Concerted Action no 10 Status Papers. Methods for assessment of micronutrient status. Int J Vitam Nutr Res 63:247, 1993.
59. Van den Berg M, Boers GHJ, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CDA: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25:176, 1995.
60. Ballas SK, Saida P: Thrombosis, megaloblastic anemia and sickle cell disease: A unified hypothesis. Br J Haematol 96:872, 1997.